These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 1717712)

  • 21. Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.
    McKnight A; Shotton C; Cordell J; Jones I; Simmons G; Clapham PR
    J Virol; 1996 Jul; 70(7):4598-606. PubMed ID: 8676486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
    VanCott TC; Mascola JR; Kaminski RW; Kalyanaraman V; Hallberg PL; Burnett PR; Ulrich JT; Rechtman DJ; Birx DL
    J Virol; 1997 Jun; 71(6):4319-30. PubMed ID: 9151820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
    Etemad-Moghadam B; Sun Y; Nicholson EK; Karlsson GB; Schenten D; Sodroski J
    J Virol; 1999 Oct; 73(10):8873-9. PubMed ID: 10482646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    Cao J; Sullivan N; Desjardin E; Parolin C; Robinson J; Wyatt R; Sodroski J
    J Virol; 1997 Dec; 71(12):9808-12. PubMed ID: 9371651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
    Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
    J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of hypervariable domains to the conformation of a broadly neutralizing glycoprotein 120 epitope.
    Lee CN; Robinson J; Mazzara G; Cheng YL; Essex M; Lee TH
    AIDS Res Hum Retroviruses; 1995 Jul; 11(7):777-81. PubMed ID: 7546903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
    Stamatatos L; Cheng-Mayer C
    J Virol; 1995 Oct; 69(10):6191-8. PubMed ID: 7545244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
    Moore JP; Sattentau QJ; Yoshiyama H; Thali M; Charles M; Sullivan N; Poon SW; Fung MS; Traincard F; Pinkus M
    J Virol; 1993 Oct; 67(10):6136-51. PubMed ID: 7690418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
    Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
    J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ; Gorny MK; Zolla-Pazner S; Quinnan GV
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
    Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
    J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
    Robert-Guroff M; Aldrich K; Muldoon R; Stern TL; Bansal GP; Matthews TJ; Markham PD; Gallo RC; Franchini G
    J Virol; 1992 Jun; 66(6):3602-8. PubMed ID: 1374810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates.
    Devico A; Silver A; Thronton AM; Sarngadharan MG; Pal R
    Virology; 1996 Apr; 218(1):258-63. PubMed ID: 8615032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
    Callahan LN; Phelan M; Mallinson M; Norcross MA
    J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.
    Thali M; Charles M; Furman C; Cavacini L; Posner M; Robinson J; Sodroski J
    J Virol; 1994 Feb; 68(2):674-80. PubMed ID: 7507184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    Thali M; Furman C; Ho DD; Robinson J; Tilley S; Pinter A; Sodroski J
    J Virol; 1992 Sep; 66(9):5635-41. PubMed ID: 1380099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.